CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Recent advances in biomaterial designs for assisting CAR-T cell therapy towards potential solid tumor treatment.
Recent advances in biomaterial designs for assisting CAR-T cell therapy towards potential solid tumor treatment.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
CAR-T(CAR-T)细胞在血液系统恶性肿瘤的治疗中已显示出良好的疗效。然而,由于复杂的制备工艺、增殖与浸润困难、缺乏精准性以及可视化能力不足等问题,CAR-T 细胞疗法在实体瘤治疗中受到显著限制。幸运的是,近期报道显示,功能性生物材料设计如纳米颗粒、聚合物、水凝胶或可植入支架,可能具有解决上述挑战的潜力。在本综述中,我们旨在总结用于辅助CAR-T 细胞疗法以潜在治疗实体瘤的功能性生物材料设计的最新进展。首先,通过在体内和体外实现高效的CAR基因递送,功能性生物材料可以简化CAR-T 细胞疗法中困难的制备过程。其次,它们还可以作为药物和生物活性分子的载体,促进CAR-T 细胞的增殖和浸润。
此外,一些具有免疫调节特性的功能性生物材料设计可以调节肿瘤微环境,从而为联合治疗提供平台,或通过协同治疗效果提高CAR-T 细胞疗法的疗效。
最后,还将讨论基于生物材料的CAR-T 疗法当前面临的挑战,这可能有助于未来实体瘤治疗中CAR-T 疗法的设计。
Chimeric antigen receptor T (CAR-T) cells have shown promising outcomes in the treatment of hematologic malignancies.
However, CAR-T cell therapy in solid tumor treatment has been significantly hindered, due to the complex manufacturing process, difficulties in proliferation and infiltration, lack of precision, or poor visualization ability. Fortunately, recent reports have shown that functional biomaterial designs such as nanoparticles, polymers, hydrogels, or implantable scaffolds might have potential to address the above challenges.
In this review, we aim to summarize the recent advances in the designs of functional biomaterials for assisting CAR-T cell therapy for potential solid tumor treatments. Firstly, by enabling efficient CAR gene delivery in vivo and in vitro , functional biomaterials can streamline the difficult process of CAR-T cell therapy manufacturing. Secondly, they might also serve as carriers for drugs and bioactive molecules, promoting the proliferation and infiltration of CAR-T cells.
Furthermore, a number of functional biomaterial designs with immunomodulatory properties might modulate the tumor microenvironment, which could provide a platform for combination therapies or improve the efficacy of CAR-T cell therapy through synergistic therapeutic effects. Last but not least, the current challenges with biomaterials-based CAR-T therapies will also be discussed, which might be helpful for the future design of CAR-T therapy in solid tumor treatment.
MEMBER ACCOUNT
登录成功会直接打开下一页。